Tumor responses and preliminary survival data in a phase II trial of ofranergene obadenovec (VB-111) combined with paclitaxel in patients with recurrent platinum resistant ovarian cancer
Penson, Richard T., Berlin, Suzanne T., Hanbury, Ashley M, Gonzalez, Amalia N, Collins, Siobhan A, Birrer, Michael, Campos, Susana, Peralta, Ariana, Leubitz, Andrea R, Cohen, Yael Chava
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial
Brenner, Andrew Jacob, Cohen, Yael Chava, Vredenburgh, James J., Peters, Katherine B, Nayak, Lakshmi, Blumenthal, Deborah T., Bokstein, Felix, Breitbart, Eyal, Bangio, Livnat, Sher, Naamit, Leubitz, Andrea R, Yust-Katz, Shlomit, Peretz, Idit, Freedman, Laurence S, Olmer, Liraz, Wen, Patrick Y.
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article